Search

Your search keyword '"Golovchenko, Oleksandr"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Golovchenko, Oleksandr" Remove constraint Author: "Golovchenko, Oleksandr"
30 results on '"Golovchenko, Oleksandr"'

Search Results

1. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

3. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

4. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

5. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

7. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

8. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

9. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

11. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

12. Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies

13. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

15. New Prospective Phosphodiesterase Inhibitors: Phosphorylated Oxazole Derivatives in Treatment of Hypertension.

16. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

17. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

19. Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY

21. Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

23. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm

24. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

25. Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

26. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

30. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

Catalog

Books, media, physical & digital resources